193 related articles for article (PubMed ID: 29391331)
1. Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.
Onaka T; Kitagawa T; Kawakami C; Yonezawa A
Turk J Haematol; 2018 May; 35(2):135-136. PubMed ID: 29391331
[No Abstract] [Full Text] [Related]
2. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
3. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
Corey K; Cook D; Bekker J; Mugnaini E; Lin JH
JAMA Dermatol; 2014 Feb; 150(2):210-2. PubMed ID: 24352253
[No Abstract] [Full Text] [Related]
4. Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma.
Wolf S; Goiriz R; Dhairyawan R; Paige D; Rizvi H; Haroon A; Montoto S
Clin Exp Dermatol; 2019 Jul; 44(5):562-564. PubMed ID: 30430604
[No Abstract] [Full Text] [Related]
5. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
[No Abstract] [Full Text] [Related]
6. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
7. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
[TBL] [Abstract][Full Text] [Related]
8. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
9. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
11. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.
Broccoli A; Derenzini E; Pellegrini C; Narducci R; Stefani G; Casadei B; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):493-5. PubMed ID: 23726017
[No Abstract] [Full Text] [Related]
12. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Broccoli A; Pellegrini C; Di Rocco A; Puccini B; Patti C; Gini G; Mannina D; Tani M; Rusconi C; Romano A; Vanazzi A; Botto B; Carlo-Stella C; Hohaus S; Musto P; Mazza P; Molica S; Corradini P; Fama A; Gaudio F; Merli M; Gravetti A; Gritti G; Arcari A; Tosi P; Liberati AM; Pinto A; Pavone V; Gherlinzoni F; Naso V; Volpetti S; Trentin L; Goldaniga MC; Bonfichi M; De Renzo A; Schiavotto C; Spina M; Storti S; Carella AM; Stefoni V; Argnani L; Zinzani PL
Haematologica; 2017 Nov; 102(11):1931-1935. PubMed ID: 28775121
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.
Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ
Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137
[No Abstract] [Full Text] [Related]
14. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
17. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
Monjanel H; Deville L; Ram-Wolff C; Venon MD; Franchi P; Benet C; de Kerviler E; Malphettes M; Thieblemont C; Brice P
Br J Haematol; 2014 Jul; 166(2):306-8. PubMed ID: 24673542
[No Abstract] [Full Text] [Related]
19. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.
Sasapu A; Dunn ALJ; Gardner J; Wong HK
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290015
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]